CR20140364A - Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca - Google Patents

Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca

Info

Publication number
CR20140364A
CR20140364A CR20140364A CR20140364A CR20140364A CR 20140364 A CR20140364 A CR 20140364A CR 20140364 A CR20140364 A CR 20140364A CR 20140364 A CR20140364 A CR 20140364A CR 20140364 A CR20140364 A CR 20140364A
Authority
CR
Costa Rica
Prior art keywords
synthetic
apeline
mimetics
treatment
heart failure
Prior art date
Application number
CR20140364A
Other languages
English (en)
Inventor
Andrei Golosov
Philipp Grosche
Qi-Ying Hu
Hidetomo Imase
David Thomas Parker
Kayo Yasoshima
Frederic Zecri
Hongjuan Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997598&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140364(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20140364A publication Critical patent/CR20140364A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
    • A61M16/0816—Joints or connectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057—Pumps therefor
    • A61M16/0066—Blowers or centrifugal pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices
    • A61M16/201—Controlled valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La invención proporciona un polipéptido sintético de la fórmulaI':I' o una amida, un éster o una sal del mismo, en donde X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 y X13 se definen en la presente. Los polipéptidos son agonistas del receptor de APJ.
CR20140364A 2012-01-27 2014-07-28 Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca CR20140364A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261591557P 2012-01-27 2012-01-27
US201261717760P 2012-10-24 2012-10-24
US201261731697P 2012-11-30 2012-11-30
PCT/IB2013/050666 WO2013111110A2 (en) 2012-01-27 2013-01-25 Synthetic apelin mimetics for the treatment of heart failure

Publications (1)

Publication Number Publication Date
CR20140364A true CR20140364A (es) 2014-11-17

Family

ID=47997598

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140364A CR20140364A (es) 2012-01-27 2014-07-28 Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca

Country Status (43)

Country Link
US (4) US8673848B2 (es)
EP (1) EP2807183B1 (es)
JP (2) JP6313222B2 (es)
KR (2) KR102068370B1 (es)
CN (1) CN104220452B (es)
AP (1) AP2014007846A0 (es)
AR (1) AR089808A1 (es)
AU (1) AU2013213265C1 (es)
BR (1) BR112014018306A8 (es)
CA (1) CA2862240A1 (es)
CL (1) CL2014001994A1 (es)
CO (1) CO7020879A2 (es)
CR (1) CR20140364A (es)
CU (1) CU24266B1 (es)
CY (1) CY1120239T1 (es)
DK (1) DK2807183T3 (es)
EA (1) EA027853B1 (es)
EC (1) ECSP14016014A (es)
ES (1) ES2670832T3 (es)
GT (1) GT201400166A (es)
HK (1) HK1200470A1 (es)
HR (1) HRP20180806T1 (es)
HU (1) HUE039137T2 (es)
IL (1) IL233792B (es)
JO (1) JO3380B1 (es)
LT (1) LT2807183T (es)
MX (1) MX351569B (es)
MY (1) MY172268A (es)
NZ (1) NZ627772A (es)
PE (1) PE20142194A1 (es)
PH (1) PH12014501701A1 (es)
PL (1) PL2807183T3 (es)
PT (1) PT2807183T (es)
RS (1) RS57200B1 (es)
SG (1) SG11201404369PA (es)
SI (1) SI2807183T1 (es)
TN (1) TN2014000318A1 (es)
TR (1) TR201807309T4 (es)
TW (1) TWI576356B (es)
UA (1) UA116196C2 (es)
UY (1) UY34593A (es)
WO (1) WO2013111110A2 (es)
ZA (1) ZA201405400B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US10286167B2 (en) 2011-07-13 2019-05-14 Fisher & Paykel Healthcare Limited Impeller and motor assembly
UY35144A (es) * 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US8921307B2 (en) * 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
AU2013350802B2 (en) * 2012-11-30 2016-07-14 Novartis Ag Methods for making conjugates from disulfide-containing proteins
AU2013365897A1 (en) 2012-12-18 2015-07-16 Fisher & Paykel Healthcare Limited Impeller and motor assembly
WO2014099984A1 (en) * 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
JP6525951B2 (ja) 2013-03-14 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アペリン融合タンパク質およびその使用
EP3024846A1 (en) * 2013-07-25 2016-06-01 Novartis AG Cyclic apelin derivatives for the treatment of heart failure
MX2016001021A (es) * 2013-07-25 2016-08-03 Novartis Ag Bioconjugados de polipeptidos de apelina sinteticos.
US9683018B2 (en) * 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
KR20160031551A (ko) * 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
BR112016011401A2 (pt) 2013-11-20 2017-09-26 Regeneron Pharma moduladores de aplnr e utilizações dos mesmos
KR20160088429A (ko) 2013-11-26 2016-07-25 노파르티스 아게 케톤-변형된 폴리펩티드에 대한 옥심 접합을 위한 방법
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
AU2015237357B2 (en) * 2014-03-25 2019-04-18 Lanthiopep B.V. Cyclic apelin analogs
GB201407532D0 (en) 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
WO2015179734A1 (en) * 2014-05-23 2015-11-26 Novartis Ag Methods for making conjugates from disulfide-containing proteins
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6675333B2 (ja) 2014-06-23 2020-04-01 ノバルティス アーゲー 部位特異的タンパク質修飾
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
USD790683S1 (en) * 2015-03-11 2017-06-27 Resmed Limited Pressurized air delivery console
US10426818B2 (en) * 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
ME03733B (me) 2015-05-20 2021-01-20 Amgen Inc Agonisti triazola apj receptora
WO2017140684A2 (en) 2016-02-15 2017-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
CA3040517A1 (en) 2016-10-19 2018-04-26 Avive, Inc. Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
US11400247B2 (en) 2016-12-22 2022-08-02 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
EP3615820A4 (en) 2017-04-23 2021-01-06 Fisher & Paykel Healthcare Limited BREATHING ASSISTANCE DEVICE
CA3073806A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
MX2021005559A (es) 2018-11-14 2021-09-10 Altavant Sciences Gmbh Compuesto espirocíclico cristalino, forma de dosificación que lo contiene, procedimiento de uso en el tratamiento de una enfermedad y procedimiento de recristalización.
ES2957324T3 (es) * 2019-02-27 2024-01-17 Air Liquide Dispositivo de suministro de gas con bolsa deformable y sensores de presión diferencial
CN112007027B (zh) * 2020-09-14 2022-07-15 长春金赛药业有限责任公司 含酯基芳香丙酰胺类化合物及其代谢产物在制备治疗心衰药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012635A2 (en) 1992-11-17 1994-06-09 Icos Corporation Novel seven transmembrane receptors
GB2281513B (en) * 1993-08-31 1997-12-03 Ulco Eng Pty Ltd Ventilator disconnect alarm
EP0645119A3 (en) * 1993-09-27 1998-04-15 Ohmeda Inc. Disabling apnoea volume software
US5598838A (en) * 1995-04-07 1997-02-04 Healthdyne Technologies, Inc. Pressure support ventilatory assist system
CA2222830C (en) * 1996-12-02 2004-03-30 Fisher & Paykel Limited Humidifier sleep apnea treatment apparatus
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1040189B1 (en) 1997-12-24 2008-01-09 Takeda Pharmaceutical Company Limited Polypeptides, their production and use
AU5759399A (en) 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative
KR20010080015A (ko) 1998-10-05 2001-08-22 다케다 야쿠힌 고교 가부시키가이샤 Ｎ-말단 메티오닌의 제거방법
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
DE60119714T2 (de) 2000-03-23 2006-09-07 Takeda Chemical Industries, Ltd. Peptidderivat
AU2001264937A1 (en) 2000-05-23 2001-12-03 Genaissance Pharmaceuticals, Inc. Haplotypes of the agtrl1 gene
US6349724B1 (en) * 2000-07-05 2002-02-26 Compumedics Sleep Pty. Ltd. Dual-pressure blower for positive air pressure device
US7574368B2 (en) * 2000-12-15 2009-08-11 Ric Investments, Llc System and method for upgrading a pressure generating system
WO2003092581A2 (en) 2001-07-16 2003-11-13 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US7157035B2 (en) * 2001-12-14 2007-01-02 Fisher & Paykel Healthcare Limited Method of forming a respiratory conduit
TW545624U (en) * 2002-01-18 2003-08-01 Enermax Technology Corp Computer environment temperature/rotation speed display and self-adjusted fan speed device
WO2003063892A1 (fr) 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Utilisation d'apeline
US7086399B2 (en) * 2002-05-29 2006-08-08 Fisher & Paykel Healthcare Limited Apparatus for delivery of humidified gases therapy, associated methods and analysis tools
WO2004081198A2 (en) 2003-03-12 2004-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis with apelin compositions
EP1656560A2 (en) 2003-05-22 2006-05-17 Agilent Technologies, Inc. Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof
US7947280B2 (en) 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
EP1520861A1 (en) 2003-09-11 2005-04-06 Aventis Pharma Deutschland GmbH Test system for the identification of APJ receptor ligands
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
AU2005265164A1 (en) 2004-06-17 2006-01-26 Musc Foundation For Research Development Non-natural amino acids
US20060045880A1 (en) 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
JP2008013436A (ja) 2004-10-14 2008-01-24 Kanazawa Univ 血管形成促進剤
US20110097710A1 (en) 2004-10-26 2011-04-28 Macrae Calum A Methods for detecting atrial fibrillation and related conditions
US20060159676A1 (en) 2005-01-14 2006-07-20 Krieg Paul A Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1876448A1 (en) 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
US7736346B2 (en) 2005-10-18 2010-06-15 Biocardia, Inc. Bio-interventional therapeutic treatments for cardiovascular diseases
US20080031871A1 (en) 2006-02-21 2008-02-07 Allen Margaret L Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene
US20090324610A1 (en) 2006-04-25 2009-12-31 Kyushu Univeristy, National University Corporation Gene associated with arteriosclerotic disease, and use thereof
KR20100059864A (ko) 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｔｒａｐ-１４
WO2009033819A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20110123534A1 (en) 2007-12-12 2011-05-26 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
WO2009075566A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
AU2009311640B2 (en) 2008-11-04 2013-09-26 Anchor Therapeutics, Inc. APJ receptor compounds
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
WO2011056073A2 (en) 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
WO2011133948A2 (en) 2010-04-22 2011-10-27 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
RU2457216C1 (ru) 2010-12-21 2012-07-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) Додекапептиды, обладающие кардиопротекторными свойствами
EP2802596A1 (en) 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Apj receptor compounds
MX2016001021A (es) 2013-07-25 2016-08-03 Novartis Ag Bioconjugados de polipeptidos de apelina sinteticos.
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
EP3024846A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic apelin derivatives for the treatment of heart failure
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드

Also Published As

Publication number Publication date
NZ627772A (en) 2015-11-27
CO7020879A2 (es) 2014-08-11
GT201400166A (es) 2015-10-15
ZA201405400B (en) 2016-08-31
BR112014018306A8 (pt) 2017-07-11
MY172268A (en) 2019-11-20
AP2014007846A0 (en) 2014-08-31
CU20140097A7 (es) 2015-03-30
PL2807183T3 (pl) 2018-08-31
US20170232221A1 (en) 2017-08-17
US8673848B2 (en) 2014-03-18
JP6595553B2 (ja) 2019-10-23
WO2013111110A2 (en) 2013-08-01
AU2013213265C1 (en) 2016-09-29
KR102068370B1 (ko) 2020-01-21
CL2014001994A1 (es) 2014-11-03
SG11201404369PA (en) 2014-08-28
UA116196C2 (uk) 2018-02-26
JP2015506370A (ja) 2015-03-02
HRP20180806T1 (hr) 2018-06-29
TR201807309T4 (tr) 2018-06-21
MX351569B (es) 2017-10-19
CU24266B1 (es) 2017-07-04
US20150252076A1 (en) 2015-09-10
EP2807183B1 (en) 2018-02-28
DK2807183T3 (en) 2018-06-06
IL233792B (en) 2018-04-30
AU2013213265B2 (en) 2016-05-26
LT2807183T (lt) 2018-05-10
US20140142022A1 (en) 2014-05-22
JP6313222B2 (ja) 2018-04-18
RS57200B1 (sr) 2018-07-31
AU2013213265A1 (en) 2014-09-18
KR20200003229A (ko) 2020-01-08
US9067971B2 (en) 2015-06-30
CN104220452A (zh) 2014-12-17
ECSP14016014A (es) 2015-11-30
PH12014501701A1 (en) 2014-10-13
WO2013111110A3 (en) 2013-10-31
EA027853B1 (ru) 2017-09-29
JP2018048157A (ja) 2018-03-29
KR20140117603A (ko) 2014-10-07
CA2862240A1 (en) 2013-08-01
SI2807183T1 (en) 2018-05-31
TW201335190A (zh) 2013-09-01
CY1120239T1 (el) 2019-07-10
JO3380B1 (ar) 2019-03-13
US9982017B2 (en) 2018-05-29
BR112014018306A2 (es) 2017-06-20
US20130196899A1 (en) 2013-08-01
TWI576356B (zh) 2017-04-01
EP2807183A2 (en) 2014-12-03
PT2807183T (pt) 2018-05-29
HK1200470A1 (en) 2015-08-07
PE20142194A1 (es) 2014-12-21
IL233792A0 (en) 2014-09-30
EA201491433A1 (ru) 2014-12-30
MX2014009085A (es) 2014-08-27
ES2670832T3 (es) 2018-06-01
HUE039137T2 (hu) 2018-12-28
TN2014000318A1 (en) 2015-12-21
CN104220452B (zh) 2018-01-26
UY34593A (es) 2013-09-02
AR089808A1 (es) 2014-09-17

Similar Documents

Publication Publication Date Title
CR20140364A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca
CR20160048A (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca
CU20160012A7 (es) Bioconjugados de polipéptidos de apelina sintética
ES2722799T3 (es) Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
CY1121114T1 (el) Αγωνιστες γλυκαγονης/glp-1 για τη θεραπεια της παχυσαρκιας
CL2019001465A1 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip.
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
CO7400885A2 (es) Análogos de glucagón
NI201500077A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
GT201500011A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
DK2940135T5 (da) Heterodimeriseret polypeptid
CR20150003A (es) Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huérfano rory
MY185217A (en) Analogs of glucagon exhibiting gip receptor activity
CR20120303A (es) Tratamientos para trastornos gastrointestinales
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
DK3347084T3 (da) Aortakanyle til ex vivo-organplejesystem
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
AR102658A1 (es) Composición para el tratamiento de telas
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
UY35143A (es) Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
AR083528A1 (es) Analogos de peptido insulinotropico dependiente de glucosa
DOP2013000195A (es) Compuestos novedosos en base a ureas asimetricas, y usos medicos de los mismos
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CU24630B1 (es) Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina
CL2020000812A1 (es) Semaglutida en la terapia médica.